Needham, MA and Philadelphia – Tyrogenex, a leader in the development of novel kinase inhibitors to target angiogenesis, and Xcovery, a developer of next-generation targeted therapeutics for cancer, today announced the opening of a new office in Needham, Mass., in partnership with the Massachusetts Life Sciences Center (MLSC) during the Biotechnology Industry Organization’s BIO International convention.
Michael D. Webb, president and CEO for both Tyrogenex and Xcovery, and several management and business development functions will be based in the Needham office. Tyrogenex and Xcovery also have offices in Palm Beach Gardens, Fla.
Director of Economic Development and Global Affairs at MassBio Elizabeth Steele (far left) and Vice President for Communications and Marketing at the MLSC Angus McQuilken (far right) join Acting Vice President for Business and Corporate Development for Xcovery Fred Meyer (second from left) and President and CEO of Tyrogenex and Xcovery Michael D. Webb (second from right) to announce the opening of a new office for both companies in Needham, Mass. The announcement was made today at the 2015 BIO International Convention in Philadelphia, Pennsylvania.